WO2005001023A3 - Method and carrier complexes for delivering molecules to cells - Google Patents

Method and carrier complexes for delivering molecules to cells Download PDF

Info

Publication number
WO2005001023A3
WO2005001023A3 PCT/US2004/013772 US2004013772W WO2005001023A3 WO 2005001023 A3 WO2005001023 A3 WO 2005001023A3 US 2004013772 W US2004013772 W US 2004013772W WO 2005001023 A3 WO2005001023 A3 WO 2005001023A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
carrier complexes
delivering
molecule
delivering molecules
Prior art date
Application number
PCT/US2004/013772
Other languages
French (fr)
Other versions
WO2005001023A2 (en
Inventor
Hazel Szeto
Kesheng Zhao
Alex V Birk
Hugh D Robertson
Original Assignee
Cornell Res Foundation Inc
Hazel Szeto
Kesheng Zhao
Alex V Birk
Hugh D Robertson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18162652.4A priority Critical patent/EP3381515B1/en
Priority to EP04751253.8A priority patent/EP1625149B1/en
Priority to BRPI0409911-7A priority patent/BRPI0409911A/en
Priority to CA2524258A priority patent/CA2524258C/en
Priority to EP16188609.8A priority patent/EP3167935B1/en
Priority to JP2006532552A priority patent/JP4879020B2/en
Priority to MXPA05011773A priority patent/MXPA05011773A/en
Priority to KR1020057020664A priority patent/KR101161823B1/en
Application filed by Cornell Res Foundation Inc, Hazel Szeto, Kesheng Zhao, Alex V Birk, Hugh D Robertson filed Critical Cornell Res Foundation Inc
Priority to DK04751253.8T priority patent/DK1625149T3/en
Priority to AU2004252419A priority patent/AU2004252419B2/en
Priority to NZ543410A priority patent/NZ543410A/en
Publication of WO2005001023A2 publication Critical patent/WO2005001023A2/en
Publication of WO2005001023A3 publication Critical patent/WO2005001023A3/en
Priority to HK06109744.4A priority patent/HK1089450A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)

Abstract

The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
PCT/US2004/013772 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells WO2005001023A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA05011773A MXPA05011773A (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells.
BRPI0409911-7A BRPI0409911A (en) 2003-05-01 2004-05-03 method to release a molecule into a cell, and carrier complex
CA2524258A CA2524258C (en) 2003-05-01 2004-05-03 Carrier complexes comprising cationic peptides for delivering molecules to cells
EP16188609.8A EP3167935B1 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells
JP2006532552A JP4879020B2 (en) 2003-05-01 2004-05-03 Methods for delivering molecules to cells and carrier complexes
EP18162652.4A EP3381515B1 (en) 2003-05-01 2004-05-03 Carrier complexes for delivering molecules to cells
KR1020057020664A KR101161823B1 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells
EP04751253.8A EP1625149B1 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells
DK04751253.8T DK1625149T3 (en) 2003-05-01 2004-05-03 METHOD AND carrying complexes for delivery of molecules to cells
AU2004252419A AU2004252419B2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells
NZ543410A NZ543410A (en) 2003-05-01 2004-05-03 Carrier complexes comprising at least one molecule and an aromatic cationic peptide that can cross cell membranes by an energy-independent mechanism and deliver the molecules inside the cell
HK06109744.4A HK1089450A1 (en) 2003-05-01 2006-09-01 Method and carrier complexes for delivering molecules to cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
US60/467,516 2003-05-01

Publications (2)

Publication Number Publication Date
WO2005001023A2 WO2005001023A2 (en) 2005-01-06
WO2005001023A3 true WO2005001023A3 (en) 2005-04-28

Family

ID=33551404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013772 WO2005001023A2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Country Status (18)

Country Link
US (6) US7704954B2 (en)
EP (7) EP2604286B1 (en)
JP (6) JP4879020B2 (en)
KR (1) KR101161823B1 (en)
CN (2) CN100506841C (en)
AU (1) AU2004252419B2 (en)
BR (1) BRPI0409911A (en)
CA (1) CA2524258C (en)
DK (4) DK2604285T3 (en)
ES (3) ES2694574T3 (en)
HK (6) HK1089450A1 (en)
MX (1) MXPA05011773A (en)
NZ (1) NZ543410A (en)
PL (2) PL2604285T3 (en)
PT (2) PT2604285E (en)
SI (1) SI2604285T1 (en)
WO (1) WO2005001023A2 (en)
ZA (1) ZA200509229B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845807B2 (en) 2003-05-01 2023-12-19 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (en) * 2002-01-19 2003-07-28 포휴먼텍(주) Biomolecule transduction peptide mph1-btm and biotechnological products including it
DK2865385T3 (en) 2003-02-04 2016-12-19 Cornell Res Foundation Inc Applications of the aromatic-cationic peptide
CA2554166C (en) 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
CN101296704B (en) 2005-09-16 2012-09-05 科内尔研究基金会 Methods for reducing CD36 expression
EP1942925B1 (en) * 2005-11-04 2010-08-25 Forhumantech Co., Ltd. Methods for fusion polypeptide delivery into a cell
WO2008015580A2 (en) * 2006-07-24 2008-02-07 Forhumantech. Co., Ltd. Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same
KR20090045940A (en) * 2006-08-29 2009-05-08 포휴먼텍(주) Pharmaceutical composition for suppression of apoptosis and method for delivering the same
PT2118123E (en) 2007-01-31 2016-02-10 Harvard College Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
CA2713150C (en) 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
EP2262520B1 (en) 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
WO2010034034A1 (en) * 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
DE102008061044A1 (en) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Composition with antioxidant peptides
WO2010120431A2 (en) * 2009-03-20 2010-10-21 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods for the prevention and treatment of burn injuries and secondary complications
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome
PL2470191T3 (en) 2009-08-24 2014-09-30 Stealth Peptides Int Inc Methods and compositions for preventing or treating ophthalmic conditions
JP2013506696A (en) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー Methods for preventing or treating heart failure
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3130599A1 (en) * 2010-05-03 2017-02-15 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102010461B (en) * 2010-10-11 2014-02-12 华南理工大学 Alpha spiral cation polypeptide molecule and preparation method and application thereof
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
CN107219358A (en) * 2011-03-24 2017-09-29 康奈尔大学 Aromatic-cationic peptides and application thereof
EP2720704A4 (en) * 2011-06-14 2015-06-10 Stealth Peptides Int Inc Aromatic-cationic peptides and uses of same
JP6025311B2 (en) 2011-08-01 2016-11-16 キヤノン株式会社 Ophthalmic diagnosis support apparatus and method
CN103987397A (en) 2011-09-29 2014-08-13 梅约医学教育与研究基金会 Aromatic-cationic peptides and methods for using same
CA2852454A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc Aromatic-cationic peptides and uses of same
RU2017145921A (en) 2012-02-15 2019-02-21 Эйлерон Терапьютикс, Инк. PEPTIDOMIMETIC MACROCYCLES
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP2015514134A (en) * 2012-04-12 2015-05-18 ステルス ペプチドズ インターナショナル インコーポレイテッド Aromatic cationic peptides and uses thereof
AU2013296494B2 (en) 2012-08-02 2018-04-26 Stealth Biotherapeutics Inc. Methods for treatment of atherosclerosis
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US20170081363A1 (en) * 2014-03-03 2017-03-23 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
EP3501532A3 (en) * 2014-05-28 2019-07-17 Stealth BioTherapeutics Corp Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
PL3160984T3 (en) * 2014-06-25 2021-10-25 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
PL3160985T3 (en) 2014-06-30 2021-12-27 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
BR112017019738A2 (en) 2015-03-20 2018-05-29 Aileron Therapeutics Inc peptidomimetic macrocycles and their uses
WO2016209261A1 (en) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof, and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
US10987434B2 (en) * 2015-10-21 2021-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3049099A1 (en) 2016-11-16 2018-05-24 Luca Science Inc. Method for producing myocardial stem cell for use in treatment and/or prevention of cardiac arrest
WO2018124162A1 (en) * 2016-12-28 2018-07-05 中外製薬株式会社 Self-emulsifying drug formulation for improving membrane permeability of compound
CN107230021B (en) * 2017-06-08 2020-05-26 桂林理工大学 Method for screening leakage area of water supply pipe network
CN112672765A (en) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 Conjugates
CN114901258A (en) 2019-12-27 2022-08-12 卢卡科学株式会社 Isolated mitochondria having a smaller size and lipid membrane-based vesicles encapsulating the isolated mitochondria
WO2021216499A1 (en) * 2020-04-23 2021-10-28 North Carolina State University Cell-penetrating peptide-microrna conjugates for intracellular cell delivery
GB2614162A (en) 2020-09-09 2023-06-28 Social Profit Network Methods and compositions for delivery of biotin to mitochondria

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2967069D1 (en) * 1978-01-16 1984-08-02 Univ Boston Effecting cellular uptake of molecules
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
NL9001639A (en) 1990-07-19 1992-02-17 Amc Amsterdam PT-CONTAINING COMPOUND, METHOD FOR PREPARING IT, AND USE OF SUCH COMPOUNDS.
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (en) 1994-02-21 1995-08-22 Astra Aktiebolag New peptide opioids for the treatment of pain and their use
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002512954A (en) 1998-04-24 2002-05-08 マイトコー Compounds and methods for treating mitochondrial-related diseases
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (en) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
ATE432993T1 (en) 1999-10-04 2009-06-15 Univ New Jersey Med TAR RNA BINDING PEPTIDES
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
DE60143945D1 (en) * 2000-07-18 2011-03-10 Cornell Res Foundation Inc MEDICAL USE OF AGONISTS OF THE MU-OPIOID RECEPTOR
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
JP2005508832A (en) * 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド Transporter with arginine part at intervals
DE10121982B4 (en) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
DK2865385T3 (en) 2003-02-04 2016-12-19 Cornell Res Foundation Inc Applications of the aromatic-cationic peptide
BRPI0409911A (en) * 2003-05-01 2006-04-25 Cornell Res Foundation Inc method to release a molecule into a cell, and carrier complex
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2554166C (en) * 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CN101296704B (en) * 2005-09-16 2012-09-05 科内尔研究基金会 Methods for reducing CD36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
CA2713150C (en) * 2008-02-07 2016-01-05 Cornell University Methods for preventing or treating insulin resistance
EP2262520B1 (en) * 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
WO2020005756A1 (en) 2018-06-29 2020-01-02 Reald Spark, Llc Stabilization for privacy display

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRIN, ET AL.: "Studies on the Internalization Mechanism of Cationic Cell-penetrating Peptides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 33, 15 August 2003 (2003-08-15), pages 31192 - 31201, XP002983988 *
RICHARD ET AL.: "Cell-penetrating Peptides", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 1, January 2003 (2003-01-01), pages 585 - 590, XP002983989 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845807B2 (en) 2003-05-01 2023-12-19 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells

Also Published As

Publication number Publication date
KR101161823B1 (en) 2012-07-03
JP4879020B2 (en) 2012-02-15
US20100204448A1 (en) 2010-08-12
DK1625149T3 (en) 2016-05-30
CN101214380A (en) 2008-07-09
US10584182B2 (en) 2020-03-10
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
HK1186406A1 (en) 2014-03-14
JP5650040B2 (en) 2015-01-07
CN100506841C (en) 2009-07-01
HK1253888A1 (en) 2019-07-05
US20130085259A1 (en) 2013-04-04
EP3167935A1 (en) 2017-05-17
US11845807B2 (en) 2023-12-19
AU2004252419B2 (en) 2010-02-18
PT2604286E (en) 2014-11-28
EP2604621A1 (en) 2013-06-19
PL2604285T3 (en) 2015-02-27
JP2018158951A (en) 2018-10-11
US11180574B2 (en) 2021-11-23
WO2005001023A2 (en) 2005-01-06
EP1625149A2 (en) 2006-02-15
US20170035899A1 (en) 2017-02-09
EP2604286B1 (en) 2014-08-27
DK2604621T3 (en) 2016-02-01
AU2004252419A1 (en) 2005-01-06
EP2604287A2 (en) 2013-06-19
BRPI0409911A (en) 2006-04-25
JP2014221846A (en) 2014-11-27
ES2520816T3 (en) 2014-11-11
EP3381515B1 (en) 2020-07-08
NZ543410A (en) 2008-07-31
EP2604285A1 (en) 2013-06-19
SI2604285T1 (en) 2014-12-31
PT2604285E (en) 2014-11-12
EP2604287A3 (en) 2014-04-16
EP3381515A1 (en) 2018-10-03
JP5995930B2 (en) 2016-09-21
US20200299415A1 (en) 2020-09-24
JP2016130246A (en) 2016-07-21
HK1186482A1 (en) 2014-03-14
CA2524258C (en) 2012-08-07
EP1625149A4 (en) 2010-10-06
JP6395749B2 (en) 2018-09-26
HK1231424A1 (en) 2017-12-22
JP2011168603A (en) 2011-09-01
JP6698756B2 (en) 2020-05-27
US9315586B2 (en) 2016-04-19
US20050158373A1 (en) 2005-07-21
EP2604287B1 (en) 2016-12-07
PL2604286T3 (en) 2015-03-31
EP2604621B1 (en) 2015-10-21
ES2520815T3 (en) 2014-11-11
JP2007503461A (en) 2007-02-22
ES2694574T3 (en) 2018-12-21
JP2020105184A (en) 2020-07-09
ZA200509229B (en) 2007-03-28
EP2604285B1 (en) 2014-08-27
EP3167935B1 (en) 2018-07-18
HK1089450A1 (en) 2006-12-01
EP2604286A1 (en) 2013-06-19
DK2604286T3 (en) 2014-12-08
CA2524258A1 (en) 2005-01-06
US7704954B2 (en) 2010-04-27
MXPA05011773A (en) 2006-02-17
EP1625149B1 (en) 2016-02-17
CN1780851A (en) 2006-05-31
DK2604285T3 (en) 2014-12-01
KR20060008950A (en) 2006-01-27
HK1186407A1 (en) 2014-03-14

Similar Documents

Publication Publication Date Title
WO2005001023A3 (en) Method and carrier complexes for delivering molecules to cells
WO2005079397A3 (en) Anti-microrna oligonucleotide molecules
EP1754234A4 (en) Low platinum fuel cells, catalysts, and method for preparing the same
WO2006091231A3 (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2005103076A3 (en) Erythropoietin protein variants
WO2006138166A3 (en) Stable cyclic (alkyl)(amino) carbenes as ligands for transition metal catalysts
WO2006074440A3 (en) Fence system
EP1954086A4 (en) (u)sim card in server mode, and communication method with client
GB2422834B (en) MHC oligomer and method of making the same
FI20031887A (en) Method for Sharing Calendar Content in a Communication System, a Communication System, and a Terminal
AU2002323246A1 (en) Fuel cell vehicle with by-wire technology
WO2004061122A3 (en) Cell proliferation-related polypeptides and uses therefor
GB2448281A (en) Cross connect terminal block
WO2005008449A3 (en) Systems and methods for enhanced accounts
EP1635413A4 (en) Proton conductive film, method for producing same, and fuel cell using same
EP1705740A4 (en) Fuel for fuel cell, fuel cell and application thereof
AU2003274733A1 (en) Manufacturing process for fuel cell, and fuel cell apparatus
AU2003266666A1 (en) Fuel cell and portable device equipped with the same, and fuel cell operating method
ITTO20010247A0 (en) ELECTRICAL CONNECTOR, ESPECIALLY FOR VEHICLES.
GB2387077B (en) Foldable type portable information terminal,answer holding method used in the same,and program therefor
WO2001000799A8 (en) Novel protein and dna thereof
IT1307066B1 (en) REFRESHING BUCKET FOR BOTTLES, IN PARTICULAR DACHAMPAGNE BUCKET.
WO2003079974A3 (en) Integrin ligand
AU2003295051A1 (en) Method for expressing inducible rnai in cells, nucleic acid molecules therefor and cells transformed by said molecules
WO2008114787A1 (en) Antiviral agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2524258

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004811701X

Country of ref document: CN

Ref document number: 1020057020664

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011773

Country of ref document: MX

Ref document number: 2006532552

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 543410

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/09229

Country of ref document: ZA

Ref document number: 2004252419

Country of ref document: AU

Ref document number: 200509229

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2290/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004751253

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004252419

Country of ref document: AU

Date of ref document: 20040503

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004252419

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020057020664

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004751253

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409911

Country of ref document: BR